NIH CONFERENCE
HIV Vaccine Development: A Progress Report
Daniel F. Hoth;
Dani P. Bolognesi;
Lawrence Corey; and
Sten H. Vermund
15 October 1994 | Volume 121 Issue 8 | Pages 603-611
The development of a safe, effective preventive vaccine for human immunodeficiency virus (HIV) infection remains an area of vigorous research.Several highly innovative vaccine candidates are being developed, and more than 13 vaccine candidates have been tested in human phase I or II trials. All have produced antibody and several have produced modest neutralizing titers, but to date no reproducible evidence has suggested prolonged, high-titer neutralization across a diversity of HIV strains. Furthermore, only the live recombinant vector approaches have produced some evidence of cytotoxic T-cell responses. The principal obstacle to progress is the lack of definitive information on what constitutes a protective immune response. There is no animal model for HIV-induced disease. Hence, the identification of the correlates of immunity and more useful animal models is among the highest priorities for HIV vaccine research. Large-scale efficacy trials raise daunting scientific, ethical, and resource issues. Nonetheless, preparation in such trials is underway in order to be in a position to evaluate the most promising vaccine candidate.
Author and Article Information
 |
An edited summary of a Clinical Staff Conference held on 27 January 1993 at the National Institutes of Health, Bethesda, Maryland.
Authors who wish to cite a section of the conference and specifically indicate its author may use this example for the form of reference:
Bolognesi DP, Preclinical vaccine research, pp. 603-605. In: Hoth DF, moderator. HIV vaccine development. Ann Intern Med. 1994; 121:603-611.
Request for Reprints: Daniel Hoth, MD, Cell Genesys, 322 Lakeside Drive, Foster City, CA 94404-1146.
Article
